Brief report · 30 Dec 2024
Conference abstractPublished 8 Dec 2014
Drug discovery against category A-C pathogens through MEP pathway
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The World Health Organization estimates that around 1.5 billion people are currently infected with latent tuberculosis (TB). Each year, 8 million people develop active disease and of these approximately 20% of the cases are multiple drug resistant and 2% are extensively drug resistant. In all, the annual death toll from TB is 2-3 million people worldwide. However, in spite of recent intensive research no new classes and delivery methods of anti-TB drugs have been developed for clinical use since the 1960?s. In this context, designing, developing and delivering a new drug is very important. To date two different biosynthetic pathways have been reported leading to isopentenyldiphosphate, the universal precursor of isoprenoids. The mevalonate pathway is found in animals whereas the methylerythritol phosphate (MEP) or non-mevalonatepathway is found in many bacteria, some protozoa and plants. Since the MEP pathway is not found in mammalian cells, it is considered an attractive target for the development of antimicrobials, antimalarials and herbicidal agents; a hypothesis that is being explored by raising number of researchers recently. In recent years, we reported enantioselective synthesis of DXP, MEP, CDPME, CDPME2P and MECPP, the substrates for assay development. In addition the kinetic studies of mycobacterial DXS, IspC, IspD, IspE, and IspF were also reported while developing assay. Computational screening against 14 million compounds gave us a good drug lead. With the newly synthesized MEP, CDPME substrate and developed assay a new IspD and IspE inhibitor were discovered showing good IC50 and MIC.
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 28 Aug 2023
Metabolomics and Medicinal Chemistry: Unveiling New Pathways to Drug Discovery
Editorial · 2015
MEP Pathway: A Novel Pathway for New Antibiotics
Conference abstract · 13 Oct 2016
Anti-resistance agent discovery targeting efflux pumps of multi-drug resistant pathogens using synthetic combinatorial libraries
Commentary · 31 Mar 2023
Drug Discovery in Malaria using the cAMP Signaling Pathways
More from this journal
The newest in Medicinal Chemistry.
Brief report · 30 Jun 2026
Covalent Drugs in Medicinal Chemistry: Emerging Opportunities and Ongoing Challenges
Commentary · 29 Dec 2025
Accelerating Drug Discovery: Molecular Docking and Virtual Screening
Opinion · 29 Dec 2025
Pharmacophore Modeling: A Cornerstone of Drug Discovery
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal Chemistry
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Prabagaran Narayanasamy”

